aTyr Pharma, Inc.

Clinical trials sponsored by aTyr Pharma, Inc., explained in plain language.

aTyr Pharma, Inc. ATYR NASDAQ

A biopharmaceutical company developing novel therapies for rare respiratory and autoimmune diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

New drug aims to cut steroid use in lung sarcoidosis

Disease control Completed

This Phase 3 trial tested a drug called efzofitimod in 268 adults with pulmonary sarcoidosis, a condition that causes lung inflammation. Participants received either the drug or a placebo every 4 weeks for 48 weeks. The main goal was to see if the drug could help people safely re…

Phase 3 • Sponsor: aTyr Pharma, Inc. • Aim: Disease control

Last updated Jun 27, 2026 13:02 UTC

aTyr Pharma, Inc.

New drug aims to cut steroid use in lung sarcoidosis